{"id":"NCT00789581","sponsor":"SCRI Development Innovations, LLC","briefTitle":"A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer","officialTitle":"Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2015-12","completion":"2016-11","firstPosted":"2008-11-13","resultsPosted":"2017-04-12","lastUpdate":"2017-07-02"},"enrollment":614,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Doxorubicin","otherNames":["Adriamycin","hydroxydaunorubicin","Adriamycin PFS","Adriamycin RDF","Rubex"]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":["Endoxan","Cytoxan","Neosar","Procytox","Revimmune","Cytophosphane"]},{"type":"DRUG","name":"Ixabepilone (Ixempra)","otherNames":["Ixempra","azaepothilone B","BMS-247550"]},{"type":"DRUG","name":"Paclitaxel (Taxol)","otherNames":["Taxol"]}],"arms":[{"label":"Doxorubicin/cyclophosphamide, ixabepilone","type":"EXPERIMENTAL"},{"label":"Doxorubicin/cyclophosphamide, paclitaxel","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, Phase III, open-label, multicenter study.","primaryOutcome":{"measure":"Disease-free Survival","timeFrame":"up to 5.25 years (63 months)","effectByArm":[{"arm":"Ixabepilone","deltaMin":88.6,"sd":null},{"arm":"Paclitaxel","deltaMin":88.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":70,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["28508185"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":58,"n":305},"commonTop":["Fatigue","Nausea","Alopecia","Neutropenia","Neuropathy peripheral"]}}